Latest discoveries in ADPKD genetics

Living with PKD
Back to Search
Recorded Tuesday September 28, 2021 | 7 p.m. CDT


What is the database and what are we learning from it?

Learning objectives

  • Understand how genetic test results can tell us about a PKD patient’s disease progression.
  • Learn how to sign up to participate in genetic research.
  • Increase knowledge of PKDF’s funded research programs and projects.


11 + 8 =


Peter C. Harris, Ph.D.

Peter C. Harris, Ph.D.

Director, Mayo Clinic Translational PKD Center

The research laboratory of Peter C. Harris, Ph.D., focuses on genetic diseases of the kidney, especially PKD. Dr. Harris’ laboratory employs a range of genetic and cell biological approaches to understand the etiology and pathogenesis of these disorders. Dr. Harris’ research group previously identified the major gene for the common autosomal dominant PKD (ADPKD) and the gene for autosomal recessive PKD (ARPKD). More recently, they identified two genes for the syndromic PKD, Meckel syndrome (MKS), and two minor ADPKD-like genes.

In these disorders, Dr. Harris’ studies are focused on screening for disease-causing mutations and other variants that can modify the phenotype. By employing genotype and phenotype studies, he is determining the extent to which the variability in disease presentation and progression is explained by simple genetic factors.

Dr. Harris’ research is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). He is associate director of the Mayo Translational PKD Center, which coordinates PKD research activities at Mayo Clinic. He also hosts the PKD Foundation-funded ADPKD Mutation Database, which describes more than 2,000 variants to the ADPKD genes.

Related Resources

Manual para pacientes con ERPAD: Entender y vivir con la enfermedad renal poliquística autosómica dominante

Manual para pacientes con ERPAD: Entender y vivir con la enfermedad renal poliquística autosómica dominante

El propósito de este manual es proporcionar información sobre la enfermedad renal poliquística autosómica dominante (ERPAD). Será un documento útil para aquellas personas que tienen la enfermedad, para las que tienen riesgo de tenerla debido a un progenitor afectado, así como para los familiares y amigos involucrados. No está dirigido a los pacientes con enfermedad renal poliquística autosómica recesiva (ERPAR). Para los pacientes con esta enfermedad, hay un manual disponible en En lo sucesivo, nos referiremos a la ERPAD simplemente como ERP.



Tuesday, December 1, 2021 | 11 a.m. CST

Dr. Roman-Ulrich Müller of University Hospital Cologne gives an update on the KETO-PKD Study (begun Oct. 2020).

Understanding Lab Results

Understanding Lab Results

Tuesday, November 16, 2021 | 7 p.m. CDT

Labs provide you and your doctor with valuable information about your overall health and your kidney function. It is important to understand the labs that your doctor requests, track your results, and know when specific labs are or are not within the normal range.